Glossary – L
This glossary provides brief explanations of terms used in the Ontario Public Drug Programs web pages. To access a term definition, select the appropriate letter from the alphabet below.
| Lifetime approval |
Lifetime approval is a term used to describe the period of coverage that the CED has recommended, and that the ministry provides, for Individual Clinical Review/Exception Access requests for certain drugs and/or indications. |
| Limited use |
The CED recommends limited use drugs as having value in specific circumstances, but not appropriate for general listing in the Formulary. Limited use drugs may :
- have the potential for widespread use outside the indications for which benefit and cost-effectiveness have been demonstrated;
- be clinically useful, but associated with predictable severe adverse effects;
- be costly, and have a lower-cost alternative available as a general benefit.
Limited use products are listed in the Formulary with specific clinical criteria/conditions for use. These products will be reimbursed under the ODB program only when prescribed for an ODB-eligible recipient in accordance with the applicable criteria, after the prescriber has written the Reason for Use Code on the prescription. The ministry is reviewing limited use products and will ultimately transfer them to either general benefit or conditional listing.
|
| Line extension |
A new strength, formulation or reformulation of an existing drug product. |
|
Text Only Version
